Royalty Pharma

Sustainability Report and Carbon Intensity Rankings

Is Royalty Pharma doing their part?

Their DitchCarbon score is 48

Royalty Pharma has a DitchCarbon Score of 48 out of 100, indicating a moderate level of sustainability in their operations. This score reflects the company’s carbon intensity, suggesting there is significant room for improvement in reducing emissions. A higher score would demonstrate a stronger commitment to lowering carbon intensity and enhancing their environmental performance.

This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.

Industry emissions intensity

Very low

Low

Medium

High

Very high

Royalty Pharma is part of the research and development sector, which has a very low carbon intensity ranking compared to other industries. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.

Location emissions intensity

Very low

Low

Medium

High

Very high

Royalty Pharma operates in the United States, which has a low carbon intensity rating. This favorable rating suggests that the company’s sustainability efforts are supported by the country’s overall lower environmental impact.

Unlock 30+ emissions intelligence data points

Get the emissions intelligence you need, no surveys required.

– Historical Scope 1, 2 and 3 emissions

– Coverage of all industries, product level data

– Emissions forecasting, assurances

Unlock 30+ emissions data points on Royalty Pharma

Get the emissions intelligence you need, no surveys required.

– Historical Scope 1, 2 and 3 emissions

– Coverage of all industries, product level data

– Emissions forecasting, assurances

3.36%

...this company is doing 3.36% worse in emissions than the industry average.

Founded in 1996 and headquartered in New York, Royalty Pharma operates within the research and development sector of the biopharmaceutical industry. As a leader in acquiring economic interests in marketed and late-stage biopharmaceutical products, the company maintains a diversified portfolio that includes royalties from high-profile drugs such as Humira and Lyrica. Royalty Pharma’s innovative approach to collaborative capital investment has made it a pivotal partner for companies across various therapeutic areas in the biopharmaceutical field.

Compare Royalty Pharma with other companies in the same industry –>

emission intelligence's platform recommendations for Royalty Pharma

Electricity North West should explore opportunities for fuel switching in transportation and operations to potentially reduce their emissions by 15%.

Bad news, Royalty Pharma hasn't committed to SBTi goals yet

Royalty Pharma has not yet established specific commitments with the Science Based Targets initiative (SBTi). This means the company has not publicly defined or committed to precise targets for reducing greenhouse gas emissions in line with climate science.

Not participating

Claim this profile

Are you associate with this company?
Help us improve our data and claim this profile.

Our methodology

Read about our emission calculation methodologies, and what the DitchCarbon Score means.

Other company reports in this industry

Looking for a specific company?

Search our company directory or contact us for custom data requests.

Royalty Pharma

Sustainability Report and Carbon Intensity Rankings

Is Royalty Pharma doing their part?

Their DitchCarbon score is 48

Industry emissions intensity

Very low

Low

Medium

High

Very high

Location emissions intensity

Very low

Low

Medium

High

Very high

Unlock 30+ emissions intelligence data points

Unlock 30+ emissions data points on Royalty Pharma

...this company is doing 3.36% worse in emissions than the industry average.

emission intelligence's platform recommendations for Royalty Pharma

Bad news, Royalty Pharma hasn't committed to SBTi goals yet

Claim this profile

Our methodology

Other company reports in this industry

Looking for a specific company?

Quicklinks

Resources

Get in touch